PMV Pharmaceuticals, Inc. (PMVP)

Over the past six months, PMV Pharmaceuticals' stock price has decreased by -29.17% over the last 52 weeks, with a 52-week range between $0.81 and $1.84. In September 2025, the company announced promising rezatapopt monotherapy interim data from the PYNNACLE Phase 2 trial. In October 2025, updated data was presented at the 2025 AACR-NCI-EORTC International Conference, showing a 34% overall response rate across eight solid tumor types. Also in October 2025, OrbiMed Advisors LLC sold 1,000,000 shares of common stock for $1.52 million. In November 2025, PMV Pharmaceuticals reported its Third Quarter 2025 financial results, ending with $129.3 million in cash, projected to fund operations until the end of Q1 2027. The company reported a net loss of $58.7 million in 2024. The company discontinued the combination arm of rezatapopt with KEYTRUDA® due to insufficient clinical benefit. An interim analysis data from the Phase 2 PYNNACLE trial is expected mid-2025, and the company plans to submit a New Drug Application (NDA) for platinum-resistant or refractory ovarian cancer in the first quarter of 2027.

As a pre-commercial, clinical-stage biotech company, PMV Pharmaceuticals, Inc. does not experience traditional demand seasonality. The demand for its lead product candidate, rezatapopt, would be driven by the prevalence of cancers with the p53 Y220C mutation and the medical need for effective treatments, rather than seasonal fluctuations. The company's current activities are centered on continuous research and development, and the progression of its clinical trials, which are not subject to seasonal demand.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations. The company's lead product candidate is rezatapopt, an orally available small molecule designed to correct the misfolding of the mutant p53 protein with the Y220C mutation. Rezatapopt is currently undergoing pivotal Phase 2 clinical trials for patients with advanced solid tumors, both as a monotherapy and previously in combination with pembrolizumab. The company's pipeline also includes rezatapopt in combination with azacitidine for Relapsed/Refractory AML/MDS, and other undisclosed product candidates targeting additional p53 mutations or p53-related targets.

PMV Pharmaceuticals, Inc. is headquartered in Princeton, New Jersey. Its Phase 2 PYNNACLE trial for rezatapopt has over 90% of its sites activated across global regions, indicating an international geographic footprint for its research and development activities.

PMV Pharmaceuticals' brand reputation is tied to its scientific advancements and clinical trial progress in precision oncology. Analyst sentiment leans towards a "Hold" consensus rating. Positive clinical data from the PYNNACLE Phase 2 trial has positively impacted its reputation, while the discontinuation of the combination arm of rezatapopt with KEYTRUDA® could be perceived negatively. The company's ongoing net losses and R&D expenses contribute to a perception of high risk, and the stock's performance has been challenging.

PMV Pharmaceuticals, Inc. has significant institutional ownership, with 83 institutional owners holding 90.20% of the stock. Major institutional owners include Orbimed Advisors Llc, BML Capital Management, LLC, and Tang Capital Management Llc. Insiders hold 7.57% of the stock, with David Mack, Co-Founder, CEO, President & Director, directly holding 1,126,976 shares as of October 27, 2025.